Table 2.
Association between prevalent functional thyroid outcomes and 131I thyroid dose estimates.
| Outcome | Thyroid dose (Gy) | EOR/Gyb (95% CI) trend p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <0.1 (0.04)a | 0.1–0.249 (0.2) | 0.25–0.49 (0.4) | 0.50–0.99 (0.7) | 1.00–2.49 (1.5) | 2.50–4.99 (3.4) | 5.00–9.99 (6.7) | ≥10.0(14.2) | ||
| Hypothyroidism (n=319) | |||||||||
| Cases (%)c | 63 (1.9) | 68 (2.8) | 61 (3.0) | 58 (3.7) | 41 (3.6) | 10 (3.7) | 9 (12.2) | 9 (39.1) | |
| OR (95% CI) | 1.00 (referent) | 1.29 (0.89, 1.86) | 1.30 (0.88, 1.90) | 1.54 (1.04, 2.29) | 1.39 (0.89, 2.15) | 1.23 (0.57, 2.43) | 4.31 (1.85, 9.15) | 16.46 (6.07, 42.76) | 0.34 (0.15, 0.62) p<0.001 |
| Antibody-positive hypothyroidism (n=62) | |||||||||
| Cases (%) | 17 (0.5) | 17 (0.7) | 14 (0.7) | 9 (0.6) | 5 (0.4) | 0 | 0 | 0 | |
| OR (95% CI) | 1.00 (referent) | 1.51 (0.77, 2.95) | 1.47 (0.71, 2.98) | 1.41 (0.59, 3.13) | 1.40 (0.44, 3.74) | — | — | — | –0.07 (–0.35, 0.61) p=0.78 |
| Hyperthyroidism (n=137) | |||||||||
| Cases (%) | 46 (1.4) | 35 (1.5) | 16 (0.8) | 23 (1.4) | 16 (1.4) | 1 (0.4) | 0 | 0 | |
| OR (95% CI) | 1.00 (referent) | 0.92 (0.58, 1.45) | 0.49 (0.26, 0.87) | 0.97 (0.56, 1.64) | 1.07 (0.56, 1.94) | 0.28 (0.02, 1.35) | — | — | –0.11 (–0.28, 0.19) p=0.41 |
| Elevated ATPO (n=622) | |||||||||
| Cases (%) | 203 (6.2) | 147 (6.1) | 122 (6.0) | 85 (5.3) | 55 (4.8) | 8 (2.9) | 2 (2.7) | 0 | |
| OR (95% CI) | 1.00 (referent) | 1.03 (0.82, 1.30) | 1.02 (0.80, 1.29) | 0.96 (0.73, 1.26) | 0.96 (0.69, 1.32) | 0.61 (0.27, 1.19) | 0.62 (0.10, 2.03) | — | –0.10 (–0.16, –0.015) p=0.30 |
| AIT (n=87) | |||||||||
| Cases (%) | 20 (0.6) | 21 (0.9) | 23 (1.1) | 14 (0.9) | 6 (0.5) | 1 (0.4) | 2 (2.7) | 0 | |
| OR (95% CI) | 1.00 (referent) | 1.82 (0.97, 3.45) | 2.44 (1.30, 4.61) | 2.23 (1.06, 4.58) | 1.50 (0.53, 3.71) | 1.30 (0.07, 6.71) | 10.11 (1.43, 42.92) | — | 0.24 (–0.08, 1.06) p=0.07 |
| aMean estimate in each thyroid dose category (Gy). bExcess odds ratio (EOR) based on a linear dose–response model with adjustment for the following: for hypothyroidism, sex, age at examination by sex, oblast of residency, rural or urban residency, current smoking, year of examination, ATPO and ATG levels, urinary iodine excretion level, presence of goiter; for antibody-positive hypothyroidism, sex, age at examination, current smoking, urinary iodine excretion level, presence of goiter; for hyperthyroidism, sex, age at examination by sex, urban or rural residency, year of examination, ATPO level, urinary iodine excretion level, presence of goiter; for elevated ATPO, sex, age at examination by sex, urban or rural residency, current smoking, year and season of examination, presence of goiter; for AIT, sex, age at examination by sex, urban or rural residency, urinary iodine excretion level, presence of goiter. Trend p-values df=1. cPercent of individuals with the respective outcome in each thyroid dose category. | |||||||||